site stats

Jcog0211-di

WebPhase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : Japan clinical oncology group study JCOG0211. / Yamaguchi, Motoko; Tobinai, Kensei; Oguchi, Masahiko et al. In: Journal of Clinical Oncology, Vol. 27, No. 33, 20.11.2009, p. 5594-5600. Research output: Contribution to journal › Article ... Web23 ott 2012 · 山口氏らはJCOG0211-DI試験において、未治療限局期鼻NKTCLでAnn Arbor病期分類IE期または頸部リンパ節浸潤のIIE期の患者を対象に、RT-DeVIC療法を …

Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma

Web1 ott 2009 · phoma: Results of a phase I portion of JCOG0211-DI. Blood 106:754A, 2005 (abstr 2685) 34. A predictive model for aggressive non-Hodgkin’s. lymphoma: The … Web– JCOG0211 (PI/II) – Concurrent chemoradiotherapy (RT-2/3DeVIC) • Newly-diagnosed stage IV, relapsed/refractory NKTCL – NKTSG (Multinational trials in East Asia) – SMILE … medication for prinzmetal angina https://tycorp.net

Phase I/II Study of Concurrent Chemoradiotherapy for Localized …

Web5 ott 2009 · Purpose To explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma, we conducted a phase I/II study of concurrent … Web28 feb 2024 · In addition, in a retrospective study of 150 ENKL patients who underwent RT-DeVIC in clinical practice at 31 institutions in Japan, only 2 patients with CR to primary treatment underwent HDC/AHSCT, and 1 of those patients developed a second cancer in the radiation volume [3]. 5-year OS rates were good in both the JCOG0211 trial and the … WebAfter JCOG0211 study, 49% of RT was designed according to JCOG0211 RT protocol, while 80% or more were not compliant RT protocol before/during JCOG0211. The local control was 74% for all population, 88% of local control rate was observed in patients treated with RT compliant with JCOG0211 RT protocol (extended RT), while 70% in patients nabco seattle wa

Phase I study of dexamethasone, methotrexate, ifosfamide,

Category:Phase I/II Study of Concurrent Chemoradiotherapy for Newly …

Tags:Jcog0211-di

Jcog0211-di

Concurrent chemoradiotherapy for localized nasal natural killer/T …

Web23 ott 2012 · 山口氏らはJCOG0211-DI試験において、未治療限局期鼻NKTCLでAnn Arbor病期分類IE期または頸部リンパ節浸潤のIIE期の患者を対象に、RT-DeVIC療法を検討した。 Web– JCOG0211 (PI/II) – Concurrent chemoradiotherapy (RT-2/3DeVIC) • Newly-diagnosed stage IV, relapsed/refractory NKTCL – NKTSG (Multinational trials in East Asia) – SMILE-P1 & P2 – SMILE chemotherapy Yamaguchi M, Tobinai K, Oguchi M, et al. J Clin Oncol 2009, 2012 (correspondence) Yamaguchi M, Kwong YL, Kim WS, et al. J Clin Oncol 2011

Jcog0211-di

Did you know?

Web3 nov 2016 · Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211

WebNK/T-cell lymphoma (NKTCL) in Japan • Incidence: 1.0 - 2.6% of ML • Median age at diagnosis: 58 years Lymphoma Study Group of Japanese Pathologists. WebPhase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. Yamaguchi M, Tobinai K, …

http://www.jcog.jp/basic/achievement/lsg.html WebJCOG0211-DI Coordinating Office Department of Hematology and Oncology, Mie University Graduate School of Medicine 研究費提供組織 / Funding Source 厚生労働省

WebN Maseki's 120 research works with 5,714 citations and 2,818 reads, including: Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan ...

Web16 nov 2005 · Nasal NK/T-cell lymphoma is a rare lymphoid neoplasm, and its standard therapy has not been established. It is one of the Epstein-Barr virus (EBV) - associated … nab corporate office sydneyWebExtranodal NK/T-cell lymphoma, nasal type (ENKL), accounts for less than 3% of malignant lymphomas in Japan. Based on the results of prospective clinical trials, ENKL treatment has dramatically improved during the last decade in Japan. The Lymphoma Study Group of the Japan Clinical Oncology Group (J … medication for priapism treatmentWeb20 mag 2012 · 8050 Background: Concurrent chemoradiotherapy has been regarded as one of the standard management for localized nasal NKTCL. However, its long-term efficacy … medication for primary progressive aphasiaWeb4 ott 2024 · JCOG0211-DI M Yamaguchi, K Tobinai, M Oguchi, et al.: Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: … medication for prevent pregnancyWeb20 nov 2009 · Purpose: To explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma, we conducted a phase I/II study of concurrent … medication for preventing ear infectionWeb3 nov 2016 · Toexplorethepossibilityofmoreeffectiveinductionchemother-apy for NK-cell neoplasms, the NK-Cell Tumor Study Group, com-prising Japanese and Asian hematologists, has ... nabcot office levittownWeb8 ott 2012 · In the November 20, 2009, issue of Journal of Clinical Oncology, we reported the results of our first analysis of a phase I/II study of concurrent chemoradiotherapy for newly diagnosed localized nasal NKTCL (Japan Clinical Oncology Group study JCOG0211). 3 Our first analysis demonstrated improved overall survival (OS) and progression-free … medication for procedure anxiety